Basit öğe kaydını göster

Early Response to Everolimus Therapy Detected on Ga-68-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor

dc.contributor.authorOzkan, Elgin
dc.contributor.authorSoydal, Cigdem
dc.contributor.authorSemirgin, Sibel Ucak
dc.contributor.authorYapici, Oktay
dc.contributor.authorAtmaca, Aysegul
dc.contributor.authorDemirag, Guzin
dc.date.accessioned2020-06-21T13:32:50Z
dc.date.available2020-06-21T13:32:50Z
dc.date.issued2016
dc.identifier.issn0363-9762
dc.identifier.issn1536-0229
dc.identifier.urihttps://doi.org/10.1097/RLU.0000000000001242
dc.identifier.urihttps://hdl.handle.net/20.500.12712/13275
dc.descriptionOzkan, Elgin/0000-0001-8543-0744; Soydal, Cigdem/0000-0002-6199-8551en_US
dc.descriptionWOS: 000377695800016en_US
dc.descriptionPubMed: 27163457en_US
dc.description.abstractEverolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-68-DOTATATE PET/CT.en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.isversionof10.1097/RLU.0000000000001242en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGa-68-DOTATATE PET/CTen_US
dc.subjecteverolimusen_US
dc.subjecttreatment responseen_US
dc.titleEarly Response to Everolimus Therapy Detected on Ga-68-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumoren_US
dc.typeeditorialen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume41en_US
dc.identifier.issue7en_US
dc.identifier.startpage561en_US
dc.identifier.endpage563en_US
dc.relation.journalClinical Nuclear Medicineen_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster